FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma

Ayca Løndalen; Johan Blakkisrud; Mona-Elisabeth Revheim; Ulf Erik Madsbu; Jostein Dahle; Arne Kolstad; Caroline Stokke

doi:10.1007/s00259-020-05098-x

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of ¹⁷⁷Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma

Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1902-1914. doi: 10.1007/s00259-020-05098-x. Epub 2020 Nov 16.

Authors

Ayca Løndalen^{1

2}, Johan Blakkisrud^{3

4}, Mona-Elisabeth Revheim^{3

5}, Ulf Erik Madsbu³, Jostein Dahle⁶, Arne Kolstad⁷, Caroline Stokke^{3

4}

Affiliations

¹ Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway. aycloe@ous-hf.no.
² Faculty of Medicine, University of Oslo, Oslo, Norway. aycloe@ous-hf.no.
³ Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
⁴ Department of Physics, University of Oslo, Oslo, Norway.
⁵ Faculty of Medicine, University of Oslo, Oslo, Norway.
⁶ Nordic Nanovector ASA, Oslo, Norway.
⁷ Department of Oncology, Radiumhospital, Oslo University Hospital, Oslo, Norway.

Abstract

Purpose: ¹⁷⁷Lu-lilotomab satetraxetan targets the CD37 antigen and has been investigated in a first-in-human phase 1/2a study for relapsed non-Hodgkin lymphoma (NHL). Tumor dosimetry and response evaluation can be challenging after radioimmunotherapy (RIT). Changes in FDG PET/CT parameters after RIT and correlations with tumor-absorbed doses has not been examined previously in patients with lymphoma. Treatment-induced changes were measured at FDG PET/CT and ceCT to evaluate response at the lesion level after treatment, and correlations with tumor-absorbed doses were investigated.

Methods: Forty-five tumors in 16 patients, with different pre-treatment and pre-dosing regimens, were included. Dosimetry was performed based on multiple SPECT/CT images. FDG PET/CT was performed at baseline and at 3 and 6 months. SUV_max, MTV, TLG, and changes in these parameters were calculated for each tumor. Lesion response was evaluated at 3 and 6 months (PET_3months and PET_6months) based on Deauville criteria. Anatomical changes based on ceCT at baseline and at 6 and 12 months were investigated by the sum of perpendiculars (SPD).

Results: Tumor-absorbed doses ranged from 35 to 859 cGy. Intra- and interpatient variations were observed. Mean decreases in PET parameters from baseline to 3 months were ΔSUV_max-3months 61%, ΔMTV_3months 80%, and ΔTLG_3months 77%. There was no overall correlation between tumor-absorbed dose and change in FDG PET or ceCT parameters at the lesion level or significant difference in tumor-absorbed doses between metabolic responders and non-responders after treatment.

Conclusion: Our analysis does not show any correlation between tumor-absorbed doses and changes in FDG PET or ceCT parameters for the included lesions. The combination regimen, including cold antibodies, may be one of the factors precluding such a correlation. Increased intra-patient response with increased tumor-absorbed doses was observed for most patients, implying individual variations in radiation sensitivity or biology.

Trial registration: ClinicalTrials.gov Identifier (NCT01796171). Registered December 2012.

Keywords: 177Lu-lilotomab satetraxetan; FDG PET/CT; Non-Hodgkin lymphoma; Radioimmunotherapy; Tumor dosimetry.

Publication types

Clinical Trial, Phase I
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use
Fluorodeoxyglucose F18*
Humans
Lymphoma, Non-Hodgkin* / diagnostic imaging
Lymphoma, Non-Hodgkin* / radiotherapy
Positron Emission Tomography Computed Tomography

Substances

(177)Lu-lilotomab satetraxetan
Antibodies, Monoclonal
Fluorodeoxyglucose F18

Associated data

ClinicalTrials.gov/NCT01796171